News Digest / Ticker: PPCB

Ticker: PPCB

08:16am, Monday, Aug 25, 2025

Propanc (PPCB) nets $4M in Nasdaq debut; 45-day 150K option and PRP Phase 1B CTA set for H1 2026

Propanc Biopharma (NASDAQ: PPCB) quietly raised $4M in August. Lead PRP IV therapy targets a Phase 1B CTA in H1 2026 (30-40 pts); Rec‑PRP pharmacology due Q1 2026. Small raise fuels headline-driven volatility and dilution risk.

04:04pm, Thursday, May 15, 2025

Propanc Biopharma Reports $54.9M Loss Amid Rising Expenses, Faces Financial Struggles Ahead

Propanc Biopharma, Inc. (OTCMKTS: PPCB) has reported its financial results for the nine months ended March 31, 2025. The company focuses on developing novel cancer therapies, primarily targeting pancreatic, ovarian, and colorectal cancer with its lead candidate, PRP. Key Highlights from Q3 2025: ...